Harrow Q1 Revenue Hit by VEVYE Coverage Gap and High-Deductible Patients
Harrow's Q1 revenue fell short due to a discrete coverage gap with VEVYE and a rise in high-deductible patient receivables, pressuring total reported sales. Management highlighted accelerating underlying demand for its core ophthalmic products, citing sequential order growth for its retina and glaucoma treatment portfolio.
1. Q1 Revenue Shortfall Drivers
Harrow's first-quarter results were affected by a discrete delay in VEVYE reimbursement and a surge in patients facing high-deductible health plans, which compressed reported revenue despite stable procedure volumes.
2. Underlying Ophthalmic Demand Accelerating
Management reported that orders for core ophthalmic devices, particularly retina and glaucoma treatment systems, increased sequentially in Q1, underscoring continued market demand even as reimbursement challenges persist.